Product
Interferon beta-1a
Aliases
Interferon beta-1a-matching placebo, Rebif
Name
AVONEX
FDA Approved
Yes
7 clinical trials
2 organizations
10 indications
2 documents
Indication
Multiple SclerosisIndication
Healthy SubjectsIndication
pharmacokineticsIndication
pharmacodynamicsIndication
Nasopharyngeal CarcinomaIndication
Nasopharyngeal CancerIndication
Nasopharyngeal NeoplasmsIndication
Community-acquired PneumoniaIndication
InfluenzaIndication
COVID-19Clinical trial
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients With Relapsing Multiple SclerosisStatus: Completed, Estimated PCD: 2015-04-02
Clinical trial
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension PhaseStatus: Recruiting, Estimated PCD: 2017-07-14
Clinical trial
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple SclerosisStatus: Completed, Estimated PCD: 2015-05-12
Clinical trial
Pharmacodynamic Biomarkers to Support Biosimilar Development: Clinical Study 3 - Interferon Beta-1A and Peginterferon Beta-1AStatus: Completed, Estimated PCD: 2021-01-26
Clinical trial
Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis PatientsStatus: Recruiting, Estimated PCD: 2023-02-28
Clinical trial
Nivolumab in Combination With Cisplatin and 5-Fluorouracil as Induction Therapy in Children and Adults With EBV-positive Nasopharyngeal CarcinomaStatus: Recruiting, Estimated PCD: 2026-01-09
Clinical trial
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaStatus: Recruiting, Estimated PCD: 2026-02-01
Document
DailyMed Label: AVONEXOrganization
Biogen Inc.Document
DailyMed Label: RebifOrganization
EMD Serono, Inc.